Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma: Paris Wednesday, February 26, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour and Welfare ...

Objective: To compare the efficacy and tolerability of dexamethasone-21-palmitate and mepivacaine alone and in combination in the acute treatment of facet syndrome. Results: In all three groups ...

Let’s look specifically at dexamethasone, a common corticosteroid in emergency medicine, and use current research to describe what the drug does and look at select situations in prehospital care ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with ...

AI算力正在重塑股市格局。英为财情Investing.com旗下ProPicks AI，由先进的AI技术甄选海量股票，汇聚成6大投资组合，打造冠军业绩。仅2024年迄今的短短时间，ProPicks AI的AI选股模型就挖掘出了2支狂飙150%的股票，4支大涨30%的股票，还有3支股票也已涨超25%。下一支即将腾飞的大牛股会是谁？

德琪医药-B(06996)再涨超11%，月内股价累涨超2.1倍。截至发稿，涨11.26%，报2.47港元，成交额1051.4万港元。 消息面上，德琪医药近日公布，公司计划加大投入，整合资源成立专门的AI部门。这一举措包括本地部署DeepSeek以加速具有空间位元阻遮蔽效应的T细胞衔接器(TCE)平台后续管线研发。据悉，公司早在2021年便以天使投资人身份投资杭州德睿智药AI药物发现平台，并借此战略 ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

The leading AL Amyloidosis Companies such as Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS ...